<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)/1/
Millennium Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
0005999021
----------------------------------------
(CUSIP Number)
Samuel P. Hunt, III, Esq., PerSeptive Biosystems, Inc.
500 Old Connecticut Path, Framingham, MA 01701
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
June 19, 1997
----------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
NOTE: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
- --------------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
SCHEDULE 13D
CUSIP No. 0005999021 Page 2 of 5 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
PerSeptive Biosystems, Inc., 04-2987616
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |__|
(b) |__|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
SC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
|__|
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 806,291
--------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -0-
--------------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 806,291
--------------------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
806,291
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [_]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.81%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON *
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
SCHEDULE 13D
CUSIP No. 0005999021 Page 3 of 5 Pages
This Schedule 13D Amendment No. 1 amends the Schedule 13D filed on February
20, 1997 with the Securities and Exchange Commission (the "SEC") on behalf of
PerSeptive Biosystems, Inc. ("PerSeptive") to reflect the sale of 806,291 shares
of Issuer Common Stock by PerSeptive.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5 is amended and restated in its entirety to read as set forth below:
(a) Amount Beneficially Owned:
PerSeptive beneficially owns 806,291 shares of Issuer Common
Stock.
Percent of Class:
PerSeptive owns 2.81% of Issuer Common Stock.
(b) Number of Shares as to which such person has:
(i) sole power to vote or direct the vote: 806,291 shares
(ii) shared power to vote or direct the vote: NOT APPLICABLE
(iii)sole power to dispose or to direct the disposition of: 806,291
shares
(iv) shared power to dispose or to direct the disposition of: NOT
APPLICABLE
(c) Except as set forth herein, neither PerSeptive, nor, to PerSeptive's
knowledge, any person named in Schedule I, has effected any transaction in the
Issuer Common Stock during the past 60 days.
(d) Not applicable.
(e) Not applicable.
<PAGE>
SCHEDULE 13D
CUSIP No. 0005999021 Page 4 of 5 Pages
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
current.
Date: June 30, 1997 PERSEPTIVE BIOSYSTEMS, INC.
/s/ John F. Smith
___________________________
John F. Smith
President
<PAGE>
SCHEDULE 13D
CUSIP No. 0005999021 Page 5 of 5 Pages
<TABLE>
<CAPTION>
SCHEDULE I
----------
Name and Address of
Corporation or Other
Principal Occupation Organization in Which
Name or Employment Employed
- ------------------------ ---------------------- ------------------------
<S> <C> <C>
Noubar B. Afeyan, Ph.D. Chief Executive PerSeptive Biosystems, Inc.
Officer, Director and 500 Old Connecticut Path
Chairman of the Board Framingham, MA 01701
John F. Smith President and Director PerSeptive Biosystems, Inc.
500 Old Connecticut Path
Framingham, MA 01701
Thomas G. Ruane Senior Vice President, PerSeptive Biosystems, Inc.
Chief Financial 500 Old Connecticut Path
Officer and Treasurer Framingham, MA 01701
Bruce J. Ryan Director Amdahl Corporation
1250 East Arques Avenue
(M/S 104)
P.O. Box 3470
Sunnyvale, CA 94088-3470
Daniel I.C. Wang, Ph.D. Director Massachusetts Institute
of Technology
18 Vassar Street
Building 20A
Room 207
Cambridge, MA 02139
Edwin M. Kania, Jr. Director One Liberty Ventures
One Liberty Square
Boston, MA 02109
William F. Pounds, Ph.D. Director MIT Sloan School of
Management
50 Memorial Drive E52-472
Cambridge, MA 02142
</TABLE>
